Successful studies for rFVIIIFc and rFIXFc (Biogen/Swedish Orphan) for Haemopilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi)released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with Haemophilia. The data, from the largest phase III registrational studies conducted in Haemophilia to date, were presented this week at the 6th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).

The studies compared the pharmacokinetic activity of rFVIIIFc for Haemophilia A and rFIXFc for Haemophilia B to currently available treatments. In the studies, the long-lasting candidates stayed active in the body longer, enabling study participants to prevent bleeding with less frequent injections than are required with the current standard of care. In the A-LONG study, patients with Haemophilia A were able to use once to twice weekly prophylactic (preventative dosing) injections of rFVIIIFc while maintaining low bleeding rates. In the B-LONG study, rFIXFc allowed patients with Haemophilia B to use prophylactic injections every one to two weeks with low bleeding rates.